Edmp Inc. Sells 2,094 Shares of Bristol Myers Squibb Company $BMY

Edmp Inc. reduced its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 5.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 37,679 shares of the biopharmaceutical company’s stock after selling 2,094 shares during the quarter. Bristol Myers Squibb makes up about 1.5% of Edmp Inc.’s holdings, making the stock its 24th largest position. Edmp Inc.’s holdings in Bristol Myers Squibb were worth $1,744,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of BMY. Brighton Jones LLC lifted its holdings in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the period. GAMMA Investing LLC lifted its holdings in Bristol Myers Squibb by 18.8% during the first quarter. GAMMA Investing LLC now owns 39,685 shares of the biopharmaceutical company’s stock worth $2,420,000 after acquiring an additional 6,267 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Bristol Myers Squibb by 1.4% during the first quarter. Assenagon Asset Management S.A. now owns 65,038 shares of the biopharmaceutical company’s stock worth $3,967,000 after acquiring an additional 869 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in Bristol Myers Squibb by 17.0% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 550,613 shares of the biopharmaceutical company’s stock worth $33,582,000 after buying an additional 80,087 shares during the last quarter. Finally, Dynamic Advisor Solutions LLC increased its position in Bristol Myers Squibb by 60.0% in the first quarter. Dynamic Advisor Solutions LLC now owns 30,491 shares of the biopharmaceutical company’s stock worth $1,860,000 after buying an additional 11,437 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.07% of the stock is currently owned by company insiders.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $43.55 on Tuesday. The firm has a market capitalization of $88.63 billion, a price-to-earnings ratio of 17.56, a P/E/G ratio of 2.26 and a beta of 0.33. Bristol Myers Squibb Company has a 52-week low of $42.96 and a 52-week high of $63.33. The stock has a fifty day moving average of $46.22 and a 200 day moving average of $47.84. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter last year, the company earned $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be paid a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.7%. Bristol Myers Squibb’s payout ratio is 100.00%.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Daiwa Capital Markets downgraded Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a research report on Tuesday, August 5th. Dbs Bank raised Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Daiwa America downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Saturday, September 27th. Finally, Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fifteen have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $57.14.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.